Blood clotting research holds hope for sepsis

December 13, 2022 - 2 minutes
Photo/Shutterstock

Researchers from the University of Birmingham in the U.K., who identified a novel mechanism for platelet activation in pathogenic blood clotting (thrombosis), are now turning their attention to sepsis. 

Identified by associate professor Julie Rayes and Martina Colicchia from the Birmingham Platelet Group, and described in a recent paper in Blood, this previously unknown axis consists of platelet receptor glycoprotein I alpha (GPIbα), and an anti-microbial protein S100A8/A9, which is released from activated immune cells.  

The mechanism is not blocked by classical anti-platelet drugs currently used to treat arterial thrombosis, and is distinct from the ‘clotting cascade’ that limits blood loss following injury. 

Two platelet populations

Rayes said: “When clots are formed at the site of a vascular injury, two main populations of platelet are seen. Highly activated platelets are located at the core of the clot, while procoagulant platelets are present at the shell around the core and support the generation of fibrin which stabilizes the clot. 

“The S100A8/A9-GPIbα axis does not induce platelet aggregation but it does induce the formation of procoagulant platelets and accelerates fibrin activation and thrombosis. This axis might be more relevant in disease states where the activation of innate immune cells and platelets play a pivotal role in clotting.”  

High levels of S100A8/A9 are seen in the blood in thrombo-inflammatory diseases including myocardial infarction (MI), deep vein thrombosis (DVT) and infections such as COVID-19 and sepsis, and their presence correlates with thrombotic complications, and worse outcomes for patients. 

Content continues below

Related Content

The researchers believe this novel mechanism may be relevant in thrombosis observed under chronic inflammatory conditions and acute infections and believe that the interaction of S100A8/A9 with multiple receptors makes it an interesting target to limit both clotting and inflammation during sepsis. 

Seeking partners

Rayes said: “Thrombosis is a major complication during infection, so drugs are needed that target pathogenic clotting while maintaining vascular integrity and normal clotting process (haemostasis).  By selectively targeting S100A8/A9, we aim to target a key pathogenic inflammatory and thrombotic molecule to limit both inflammation and thrombosis during infection.”

University of Birmingham Enterprise has filed a patent application covering the targeting of the S100A8/A9-GPIbα axis in the treatment and prevention of thrombosis in chronic inflammatory and thrombotic diseases and is now seeking partners for commercial development or licensing.

You might also be interested in the following: